Novartis acquires UK biotech Myricx for as much as $1.5 billion to pursue a new class of cancer drugs.

      Novartis has reached an agreement to purchase Myricx Bio, a small British oncology firm, for a total of up to $1.5 billion, thereby incorporating an early-stage yet potentially impactful technology into its cancer treatment pipeline, which the industry is keen to broaden.

      The Swiss company will provide $1.1 billion upfront, with an additional $400 million contingent on achieving certain milestones, which aligns with the trend of large pharmaceutical firms exploring European biotech for innovative targeted therapies. This represents a gamble on scientific advances that have not yet reached patients.

      Myricx is not widely recognized, and for good reason: it is in the pre-clinical phase, meaning its leading programs have not commenced human trials. The company offers a novel payload for antibody-drug conjugates (ADCs), a class of medicines that has emerged as one of the most competitive areas in oncology.

      An ADC functions like a precision weapon, employing an antibody to transport a toxic drug directly to a tumor cell, and Myricx proposes a new type of warhead. The specific chemistry involved is complex, as Myricx is developing N-myristoyltransferase inhibitors (NMTi) to serve as the toxic aspect of its conjugates, suggesting that this method may circumvent the resistance and toxicity issues that hinder many current ADCs.

      Its two primary assets target B7-H3 and HER2, both linked to various solid tumors, representing disease areas with the highest commercial and clinical importance.

      For Novartis, the rationale is clear; large pharmaceutical companies view their own labs as one of many sources for innovation and often opt to acquire emerging technologies, especially in rapidly evolving sectors where smaller, dedicated teams may be ahead of the game.

      ADCs have garnered substantial investment industry-wide, with owning a differentiated payload platform being more advantageous than controlling another similar version of an existing drug.

      The deal also coincides with a time when the lines between biology and computational science are increasingly blurred, attracting significant investment. AI-driven drug discovery alone brought in billions in the first quarter of 2026, with various deals encompassing Anthropic’s biotech acquisition and increased activities surrounding European AI drug discovery.

      Myricx’s approach is rooted in traditional medicinal chemistry rather than artificial intelligence, but it is part of the wider trend towards innovative therapeutic methods.

      Myricx is backed by investors including Brandon Capital and Novo Holdings, which is associated with the Danish pharmaceutical industry, and this sale signifies the type of successful exit that venture capitalists in biotech typically aim for.

      Acquiring a pre-clinical company for up to $1.5 billion is a significant achievement, despite the fact that the total amount depends on milestones that might not be realized.

      This transaction is also a notable success for British life sciences, a sector that generates strong early-stage research yet often sees its most promising firms acquired by larger international entities before they can fully develop. Myricx evolved from academic research and advanced with venture funding, and its acquisition by a Swiss giant follows a familiar trend—beneficial for founders and investors but resulting in the eventual value creation being located abroad.

      This pattern has become a recurring topic in discussions about UK industrial policy. The distinction is important; the upfront $1.1 billion is a tangible transaction, whereas the additional $400 million is dependent on the success of the scientific developments, with pre-clinical assets frequently experiencing more failures than successes.

      Novartis is acquiring potential options rather than a finished product, and the deal's true value will be determined by clinical data that is still years away. The parties expect the transaction to finalize in the latter half of 2026.

      The acquisition indicates less about any specific molecule and more about the focus of major companies. Most straightforward oncology targets have already been addressed, and the new frontier relies on more sophisticated delivery methods, improved payloads, and combinations that protect healthy tissue. Novartis believes that a small British team may hold one of the solutions and has chosen to invest to discover more.